International Trade committee  For the benefit of the committee members, there's a really good article that came out a few months ago by Derek Lowe, entitled “Myths of Vaccine Manufacturing”. It is worth taking a look at in terms of what goes into manufacturing vaccines. It demonstrates that the discussion aro

International Trade committee  I would add that Canada, obviously, is a federation, and a successful life sciences strategy and policy involves the provincial governments, notably Quebec and Ontario. The governments of Ontario and Quebec—Premier Legault's and Premier Ford's governments—are actually already the

International Trade committee  Thank you very much. I appreciate your bringing that back before the committee. Ms. Fralick may also want to add to this. In any case, first of all, I take issue with the statement made with respect to the financing of the vaccine production. It's not the case that this has all

International Trade committee  Yes, precisely. They are making significant investments. They make these investments based on a playing field that they believe they understand. Intellectual property is part of that. In terms of their business planning, in terms of how they're going to map out expansions in prod

International Trade committee  Professor Evenett pointed this out as well. Sometimes having a robust pharmaceutical industry doesn't necessarily insulate you from the difficulties that can occur as a result of a global pandemic. Clearly, it's helpful for your public health policy. It's also helpful for your ec

International Trade committee  Yes, certainly. Thanks for the question. The industry has established in record-breaking time a network of voluntary licensing agreements with other parties. It's interesting that the IP always seems to be the focus of these issues. The CEO of the Serum Institute, which is a hu

International Trade committee  Yes, thank you. Thank you, Madam Chair, and thank you to the committee for allowing the IMC to speak to you today. I would just add—and this was already touched upon by some of the witnesses to the committee—that the issue of regulatory barriers and impediments to international